Restrictive Lung Disease

estrictive lung disease encompasses a wide range of conditions in which the total volume of air the lungs can hold is reduced. Unlike obstructive disorders, the limitation here lies not in airflow resistance but in diminished lung expansion, leading to reduced lung compliance and lower vital capacity. Causes can be classified as intrinsic, such as pulmonary fibrosis and sarcoidosis that directly stiffen lung tissue, or extrinsic, including obesity, neuromuscular weakness, and chest wall deformities that mechanically limit expansion. Patients often experience progressive shortness of breath, shallow breathing, and exercise intolerance, which significantly affect daily activity levels.

Diagnosis typically involves pulmonary function testing, where reductions in total lung capacity and preserved airflow differentiate restrictive lung disease from obstructive counterparts. High-resolution CT imaging and, when necessary, biopsy help clarify underlying pathology. Management strategies depend on etiology: antifibrotic medications may slow progression in interstitial lung disease, while non-invasive ventilation and physiotherapy can assist those with neuromuscular weakness. Pulmonary rehabilitation programs, nutritional optimization, and vaccinations against respiratory infections are frequently recommended as supportive measures. For advanced disease, lung transplantation may be considered when conservative therapies fail.

Emerging research is focusing on genetic drivers, immune pathways, and regenerative approaches that may one day reverse fibrosis or restore lung compliance. Restrictive lung disease continues to challenge clinicians, but evolving diagnostics and personalized interventions are offering new opportunities to preserve function and improve long-term outcomes.